{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:37:20Z","timestamp":1793709440890,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jocn.2025.111437","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T12:15:45Z","timestamp":1751458545000},"page":"111437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Costs of multiple sclerosis in Serbia"],"prefix":"10.1016","volume":"139","author":[{"given":"Jovana","family":"Ivanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Mihajlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Andabaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Jovicevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorica","family":"Maric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksa","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarlota","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Pekmezovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Drulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jocn.2025.111437_b0005","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.jocn.2025.111437_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208837","article-title":"Burden and cost of multiple sclerosis in Brazil","volume":"14","author":"Kobelt","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jocn.2025.111437_b0015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/14737167.2015.1067141","article-title":"The indirect costs of multiple sclerosis: systematic review and meta-analysis","volume":"15","author":"Stawowczyk","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.jocn.2025.111437_b0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.jocn.2025.111437_b0025","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s10198-006-0365-y","article-title":"Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis","volume":"7","author":"Kobelt","year":"2006","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jocn.2025.111437_b0030","article-title":"European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Belgium","volume":"23(2_suppl):29\u201340","author":"Dubois","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.jocn.2025.111437_b0035","article-title":"European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Germany","volume":"23(2_suppl):78\u201390","author":"Flachenecker","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.jocn.2025.111437_b0040","article-title":"European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe: results for France","volume":"23(2_suppl):65\u201377","author":"Lebrun-Frenay","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.jocn.2025.111437_b0045","article-title":"European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Spain","volume":"23(2_suppl):166\u201378","author":"Oreja-Guevara","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.jocn.2025.111437_b0050","article-title":"European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Poland","volume":"23(2_suppl):130\u201342","author":"Selmaj","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.jocn.2025.111437_b0055","article-title":"European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Hungary","volume":"23(2_suppl):91\u2013103","author":"P\u00e9ntek","year":"2017","journal-title":"Mult Scler J"},{"key":"10.1016\/j.jocn.2025.111437_b0060","article-title":"Interferon-beta and disability progression in relapsing-remitting multiple sclerosis","volume":"115(1_suppl):65\u201369","author":"Drulovic","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"issue":"11","key":"10.1016\/j.jocn.2025.111437_b0065","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jocn.2025.111437_b0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2025.111437_b0075","series-title":"EQ-5D Value Sets: Inventory","author":"Szende","year":"2007"},{"key":"10.1016\/j.jocn.2025.111437_b0080","unstructured":"The Health Care Insurance Fund. The list of reimbursed drugs \u2013 archive [in Serbian]. Available at: https:\/\/rfzo.rs\/index.php\/osiguranalica\/lekovi-info\/lekovi-actual-archiva [last accessed on 19\/3\/2025]."},{"key":"10.1016\/j.jocn.2025.111437_b0085","unstructured":"The Ministry of Finance of the Republic of Serbia. The highest approved prices for medicines [in Serbian]. Available at: https:\/\/www.zdravlje.gov.rs\/tekst\/335366\/najvise-cene-lekova.php [last accessed on 19\/3\/2025]."},{"key":"10.1016\/j.jocn.2025.111437_b0090","unstructured":"The Statistical Office of the Republic of Serbia. Average salaries in 2017 [in Serbian]. Available at: https:\/\/publikacije.stat.gov.rs\/G2018\/Pdf\/G20181016.pdf [last accessed on 19\/3\/2025]."},{"issue":"8","key":"10.1016\/j.jocn.2025.111437_b0095","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"MSCOI Study Group; European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult Scler J"},{"issue":"13","key":"10.1016\/j.jocn.2025.111437_b0100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1177\/1352458518809326","article-title":"International consensus on quality standards for brain health-focused care in multiple sclerosis","volume":"25","author":"Hobart","year":"2019","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.jocn.2025.111437_b0105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10072-019-03878-4","article-title":"Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study","volume":"40","author":"Drulovic","year":"2019","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.jocn.2025.111437_b0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ane.13516","article-title":"Impact of comorbidities on the disability progression in multiple sclerosis","volume":"145","author":"Maric","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"10.1016\/j.jocn.2025.111437_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159129","article-title":"Cost of illness of multiple sclerosis - a systematic review","volume":"11","author":"Ernstsson","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2025.111437_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101514","article-title":"The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis","volume":"38","author":"Petruzzo","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.jocn.2025.111437_b0130","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s10072-018-3551-7","article-title":"The direct costs of multiple sclerosis-study in the Czech Republic","volume":"39","author":"Maresova","year":"2018","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.jocn.2025.111437_b0135","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12883-019-1534-9","article-title":"Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database","volume":"19","author":"Kawachi","year":"2019","journal-title":"BMC Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2025.111437_b0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11910-021-01118-x","article-title":"Economics of multiple sclerosis disease-modifying herapies in the USA","volume":"21","author":"Hartung","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.jocn.2025.111437_b0145","article-title":"The socioeconomic impact of disability progression in multiple sclerosis: a retrospective cohort study of the German NeuroTransData (NTD) registry","volume":"9","author":"Dillon","year":"2023","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.jocn.2025.111437_b0150","unstructured":"MS Brain Health. Brain health: time matters in multiple sclerosis. 2015. Available from: https:\/\/www.msbrainhealth.org\/wp-content\/uploads\/2021\/05\/brain-health-time-matters-in-multiple-sclerosispolicy-report.pdf (Accessed 5 September 2024)."},{"issue":"4","key":"10.1016\/j.jocn.2025.111437_b0155","first-page":"725","article-title":"Multiple sclerosis: Etiology, symptoms, incidence and prevalence, and implications for community living and employment","volume":"52","author":"Bishop","year":"2015","journal-title":"Work"},{"issue":"2","key":"10.1016\/j.jocn.2025.111437_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MRR.0b013e32835c79ea","article-title":"Factors related to difficulties with employment in patients with multiple sclerosis: a review of 2002-2011 literature","volume":"36","author":"Schiavolin","year":"2013","journal-title":"Int J Rehabil Res"},{"issue":"4","key":"10.1016\/j.jocn.2025.111437_b0165","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jval.2016.01.002","article-title":"Health Utilities for Multiple Sclerosis","volume":"19","author":"Hawton","year":"2016","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jocn.2025.111437_b0170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/ene.12715","article-title":"Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis","volume":"23","author":"Planche","year":"2016","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.jocn.2025.111437_b0175","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1212\/WNL.53.5.1098","article-title":"Quality of life in multiple sclerosis: measuring the disease effects more broadly","volume":"53","author":"Nortvedt","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jocn.2025.111437_b0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13760-013-0191-9","article-title":"Predictive value of health-related quality of life in progression of disability and depression in persons with multiple sclerosis: a 3-year study","volume":"113","author":"Kisic Tepavcevic","year":"2013","journal-title":"Acta Neurol Belg"},{"issue":"4","key":"10.1016\/j.jocn.2025.111437_b0185","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/neurosci3040048","article-title":"Cognitive Impairment in Multiple Sclerosis: an Update on Assessment and Management","volume":"3","author":"Portaccio","year":"2022","journal-title":"NeuroSci"},{"issue":"1","key":"10.1016\/j.jocn.2025.111437_b0190","article-title":"High prevalence of fatigue in contemporary patients with multiple sclerosis","volume":"7","author":"Broch","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825004102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825004102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:36:46Z","timestamp":1757183806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825004102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"alternative-id":["S0967586825004102"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111437","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Costs of multiple sclerosis in Serbia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111437"}}